SCHEMBL26923799

SCHEMBL26923799

NC(=O)c1nccnc1NCc1ccc(Cl)c(Cl)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RPS6KB1 P23443 6/20 0.55
▸ AURKA O14965 5/20 0.55
▸ CD38 P28907 1/20 0.46
▸ FFAR1 O14842 1/20 0.45
▸ TSHR P16473 2/20 0.44
▸ KDR P35968 2/20 0.44
▸ AURKB Q96GD4 4/20 0.42
▸ SLC6A2 P23975 1/20 0.42
▸ SLC6A4 P31645 1/20 0.42
▸ SLC6A3 Q01959 1/20 0.42
▸ CHEK1 O14757 1/20 0.42
▸ ROCK2 O75116 1/20 0.42
▸ RPS6KA5 O75582 1/20 0.42
▸ MAP4K4 O95819 1/20 0.42
▸ CHEK2 O96017 1/20 0.42
▸ PIM1 P11309 1/20 0.42
▸ PRKACA P17612 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ AKT1 P31749 1/20 0.42
▸ AKT2 P31751 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29834817 1.00 RPS6KB1 (0.55) RPS6KB1AURKACD38FFAR1TSHR
SCHEMBL26923596 0.85 CYP2C9 (0.49) KDRALDH1A1FLT1
SCHEMBL26922246 0.83 RPS6KB1 (0.55) RPS6KB1AURKACD38KDRAURKB
SCHEMBL29834918 0.83 RPS6KB1 (0.55) RPS6KB1AURKACD38KDRAURKB
SCHEMBL26922526 0.80 AURKA (0.51) RPS6KB1AURKA
SCHEMBL26921354 0.79 KMT2A (0.52) FFAR1KDRSMN1; SMN2ALDH1A1
SCHEMBL26922081 0.79 KDM4E (0.51) RPS6KB1AURKAROCK2MAP4K4AKT1
SCHEMBL29834838 0.78 RPS6KB1 (0.50) RPS6KB1AURKACD38FFAR1AURKB
SCHEMBL26921049 0.78 RPS6KB1 (0.50) RPS6KB1AURKACD38FFAR1AURKB
SCHEMBL26921563 0.77 AURKA (0.55) RPS6KB1AURKACD38FFAR1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240093191-A1 COMPOSITIONS AND METHODS FOR TREATING DISEASE ASSOCIATED WITH DUX4 OVEREXPRESSION RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (US) 2024-03-21 — — US disclosed
EP-4288539-A1 COMPOSITIONS AND METHODS FOR TREATING DISEASE ASSOCIATED WITH DUX4 OVEREXPRESSION Research Institute at Nationwide Children's Hospital (US) 2023-12-13 — — EP disclosed
Send feedback